Furlong, PA, United States of America

Dong Cheng



 

Average Co-Inventor Count = 3.5

ph-index = 3

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 2007-2015

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovations of Dong Cheng

Introduction

Dong Cheng is a prominent inventor based in Furlong, PA (US). He has made significant contributions to the field of medicinal chemistry, holding a total of 7 patents. His work primarily focuses on developing novel compounds that have therapeutic applications.

Latest Patents

One of his latest patents is related to Aryl dihydropyridinones and piperidinone MGAT2 inhibitors. This invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, which are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors that may be used as medicaments. Another significant patent involves the Adiponectin receptor variant, AdipoR2v2. This invention provides novel polynucleotides encoding various polypeptides related to human and mouse AdipoR receptors. It also includes vectors, host cells, antibodies, and methods for producing these polypeptides, which can be applied in diagnostic and therapeutic methods for various diseases.

Career Highlights

Dong Cheng is currently employed at Bristol-Myers Squibb Company, where he continues to innovate and develop new therapeutic solutions. His work has been instrumental in advancing the understanding of metabolic diseases and their treatment.

Collaborations

He has collaborated with notable coworkers such as Ning Lee and John N Feder, contributing to a dynamic research environment that fosters innovation.

Conclusion

Dong Cheng's contributions to the field of medicinal chemistry through his patents and collaborations highlight his role as a leading inventor. His work continues to impact the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…